ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

HYZAAR
Hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

HYZAAR Rx

Generic Name and Formulations:
Losartan potassium, hydrochlorothiazide; 50mg/12.5mg, 100mg/12.5mg, 100mg/25mg; tabs.

Company:
Merck & Co., Inc.

e-Prescribe this drug via Surescripts


Therapeutic Use:

Indications for HYZAAR:

Hypertension (not for initial therapy unless HTN is severe). To reduce stroke in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients.

Adult Dose for HYZAAR:

≥18yrs: One 50–12.5mg tab once daily; may increase after about 3 weeks (2–4 weeks for severe HTN) to two 50–12.5mg tabs once daily or one 100–25mg tab once daily. Titrate components: see full labeling. HTN with LVH: switch from losartan monotherapy (see full labeling). Severe renal impairment (CrCl<30mL/min): not recommended.

Children's Dose for HYZAAR:

<18yrs: not established.

Pharmacological Class:

Angiotensin II receptor blocker + diuretic.

Contraindications:

Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity; discontinue as soon as pregnancy is detected. Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal impairment: monitor for worsening renal function. Hepatic impairment. Severe CHF. Renal artery stenosis. Asthma. SLE. Gout. Diabetes. Postsympathectomy. Acute myopia. Secondary angle-closure glaucoma. Pregnancy (Cat.C in 1st trimester, Cat.D in 2nd and 3rd trimesters). Nursing mothers: not recommended.

Interactions:

See Contraindications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Orthostatic hypotension with alcohol, other CNS depressants. Potentiates other antihypertensives, tubocurarine. Hypokalemia with corticosteroids, ACTH. May antagonize pressor amines (eg, norepinephrine). Adjust antihyperglycemics. May increase digitalis, lithium toxicity (monitor). May interfere with parathyroid tests.

Adverse Reactions:

Dizziness, abdominal pain, palpitations, back pain, sinusitis, cough, upper respiratory infection, rash, hyperkalemia; angioedema, syncope (discontinue if occurs), rhabdomyolysis (rare).

Metabolism:

Hepatic (CYP2C9, 3A4).

Elimination:

Fecal, renal.

Generic Availability:

YES

How Supplied:

Tabs—30, 90, 1000


Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs